Spatial biology company Resolve Biosciences is building up capital to accelerate its development of “Genomics 3.0.that the first animal gene was ever cloned. Researchers at Stanford and the University of California at San Francisco accomplished this by taking a gene from a tree frog and fusing it with the genome of a bacteria. This, says Jason Gammack, cofounder and CEO of Resolve Biosciences, was the beginning of “Genomics 1.0.
For example, he says, in a patient with cancer, a tissue sample is taken and the genetic material is extracted from it outside the body. Which causes researchers to miss the important context of what’s happening inside the body. That’s where his company, Resolve Biosciences, comes in. Its technology is in the field of “spatial biology” or what Gammack calls “Genomics 3.
On Monday, the German-based company announced that it has raised a $71 million series B round led by Patient Square Capital and including participation from NRW.BANK, Alafi Capital, EDBI and PS Capital. This new financing brings the company’s total backing to over $100 million. That’s a larger round than usual for the spatial biology industry–a report from Outcome Capital found that the average investment in this space is only around $33 million.
Right now, the market for spatial biology is still fairly small: an article earlier this year in European Biotechnology estimated the global market size to be around $250 million, with a projection of close to $500 million by 2028. That’s in part because right now, most adopters of this technology are basic researchers like universities and similar academic institutions.
ra ra rasputin?
30% works fine
Good luck with that bruh